Vor Biopharma Inc

NASDAQ VOR

Data sourced from

and

Download Data

Vor Biopharma Inc Days in Inventory for the Trailing 12 Months (TTM) ending March 31, 2024

Vor Biopharma Inc Days in Inventory is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The days in inventory ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing 365 by the ratio of cost of revenue to the average of inventory and other current assets. This ratio indicates the efficiency of inventory management and the company's ability to convert inventory into sales within a specific period. A lower number of days in inventory is generally preferable.

NASDAQ: VOR

Vor Biopharma Inc

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees	168
Sector	Healthcare
Industry	Biotechnology

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends